Exclusive Summary

• Backed by US-FDA GMP certification and an anticipated US ANDA in Q1 2026, enabling accelerated global registrations via regulatory reliance pathways.
• Perfectly timed for the 2026 patent cliff, penetrating a $1.3+ billion Multiple Myeloma market with a highly favorable early-generic competitive landscape.
• Serves as a vital backbone therapy highly recommended by NCCN/ESMO guidelines for Relapsed/Refractory Multiple Myeloma (~176,000 global incident cases annually).
• High manufacturing barriers for lyophilized injectables combined with the clinically preferred 60mg strength offer massive cost savings over the originator, securing lucrative margins for early distributors.